C95 COPD ADVANCES IN THERAPY: A Randomized Controlled Trial Of Azd7624, An Inhaled P38 Map Kinase Inhibitor, In COPD Patients On Ics/laba With A History Of Frequent Exacerbations

Naimish.Patel@astrazeneca.com Prior study has shown that p38 MAP kinase (MAPK) is upregulated in alveolar macrophages in patients with COPD, and p38 activation increases with COPD severity. Events of rash and elevated liver enzymes that have been associated with oral p38 inhibitors were in infrequen...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Main Authors: Make, B J, Patel, N, Cunoosamy, D, Brown, M N, Fageras, M, Lundin, S, Asimus, S, Palmer, R, Taib, Z, Jansson, P, Rennard, S I
Format: Article
Language:English
Subjects:
Chronic obstructive pulmonary disease
Kinases
Respiratory therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page
container_title American journal of respiratory and critical care medicine
container_volume 195
creator Make, B J
Patel, N
Cunoosamy, D
Brown, M N
Fageras, M
Lundin, S
Asimus, S
Palmer, R
Taib, Z
Jansson, P
Rennard, S I
description Naimish.Patel@astrazeneca.com Prior study has shown that p38 MAP kinase (MAPK) is upregulated in alveolar macrophages in patients with COPD, and p38 activation increases with COPD severity. Events of rash and elevated liver enzymes that have been associated with oral p38 inhibitors were in infrequent (
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1926719110</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1926719110</sourcerecordid><originalsourceid>FETCH-proquest_journals_19267191103</originalsourceid><addsrcrecordid>eNqNjd9OwjAYxRujiYi-w5d4y2K7P4x515SRESNbcPHPFelYCSWzxbYkyGP5hHbBB_DqO_nO75xzgQYkiZIgzlJ86TVOoyCOs_drdGPtDmMSTggeoB-WJcDKagp0-koXLH-B-QLqIl_S6uMRKCy5avWnPIkWmFbO6K7zsjaSd1BugJ7adBzGI6AK5mrLe7OKJvDM9_AkFbeif8tGOm1GXp63Ku6kUM5C6VNr-9DxhsObdFs_WEjr2e--fGbE18FzkB_5WpjGp7Syt-hqwzsr7v7uEN3P8poVwd5oj1u32umDUd5akSwcpyQjBEf_o34BJrdcwg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1926719110</pqid></control><display><type>article</type><title>C95 COPD ADVANCES IN THERAPY: A Randomized Controlled Trial Of Azd7624, An Inhaled P38 Map Kinase Inhibitor, In COPD Patients On Ics/laba With A History Of Frequent Exacerbations</title><source>Freely Accessible Journals</source><source>EZB Electronic Journals Library</source><creator>Make, B J ; Patel, N ; Cunoosamy, D ; Brown, M N ; Fageras, M ; Lundin, S ; Asimus, S ; Palmer, R ; Taib, Z ; Jansson, P ; Rennard, S I</creator><creatorcontrib>Make, B J ; Patel, N ; Cunoosamy, D ; Brown, M N ; Fageras, M ; Lundin, S ; Asimus, S ; Palmer, R ; Taib, Z ; Jansson, P ; Rennard, S I</creatorcontrib><description>Naimish.Patel@astrazeneca.com Prior study has shown that p38 MAP kinase (MAPK) is upregulated in alveolar macrophages in patients with COPD, and p38 activation increases with COPD severity. Events of rash and elevated liver enzymes that have been associated with oral p38 inhibitors were in infrequent (&lt;5%) and not different between the treatment arms.</description><identifier>ISSN: 1073-449X</identifier><identifier>EISSN: 1535-4970</identifier><language>eng</language><publisher>New York: American Thoracic Society</publisher><subject>Chronic obstructive pulmonary disease ; Kinases ; Respiratory therapy</subject><ispartof>American journal of respiratory and critical care medicine, 2017-01, Vol.195</ispartof><rights>Copyright American Thoracic Society 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Make, B J</creatorcontrib><creatorcontrib>Patel, N</creatorcontrib><creatorcontrib>Cunoosamy, D</creatorcontrib><creatorcontrib>Brown, M N</creatorcontrib><creatorcontrib>Fageras, M</creatorcontrib><creatorcontrib>Lundin, S</creatorcontrib><creatorcontrib>Asimus, S</creatorcontrib><creatorcontrib>Palmer, R</creatorcontrib><creatorcontrib>Taib, Z</creatorcontrib><creatorcontrib>Jansson, P</creatorcontrib><creatorcontrib>Rennard, S I</creatorcontrib><title>C95 COPD ADVANCES IN THERAPY: A Randomized Controlled Trial Of Azd7624, An Inhaled P38 Map Kinase Inhibitor, In COPD Patients On Ics/laba With A History Of Frequent Exacerbations</title><title>American journal of respiratory and critical care medicine</title><description>Naimish.Patel@astrazeneca.com Prior study has shown that p38 MAP kinase (MAPK) is upregulated in alveolar macrophages in patients with COPD, and p38 activation increases with COPD severity. Events of rash and elevated liver enzymes that have been associated with oral p38 inhibitors were in infrequent (&lt;5%) and not different between the treatment arms.</description><subject>Chronic obstructive pulmonary disease</subject><subject>Kinases</subject><subject>Respiratory therapy</subject><issn>1073-449X</issn><issn>1535-4970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqNjd9OwjAYxRujiYi-w5d4y2K7P4x515SRESNbcPHPFelYCSWzxbYkyGP5hHbBB_DqO_nO75xzgQYkiZIgzlJ86TVOoyCOs_drdGPtDmMSTggeoB-WJcDKagp0-koXLH-B-QLqIl_S6uMRKCy5avWnPIkWmFbO6K7zsjaSd1BugJ7adBzGI6AK5mrLe7OKJvDM9_AkFbeif8tGOm1GXp63Ku6kUM5C6VNr-9DxhsObdFs_WEjr2e--fGbE18FzkB_5WpjGp7Syt-hqwzsr7v7uEN3P8poVwd5oj1u32umDUd5akSwcpyQjBEf_o34BJrdcwg</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Make, B J</creator><creator>Patel, N</creator><creator>Cunoosamy, D</creator><creator>Brown, M N</creator><creator>Fageras, M</creator><creator>Lundin, S</creator><creator>Asimus, S</creator><creator>Palmer, R</creator><creator>Taib, Z</creator><creator>Jansson, P</creator><creator>Rennard, S I</creator><general>American Thoracic Society</general><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20170101</creationdate><title>C95 COPD ADVANCES IN THERAPY: A Randomized Controlled Trial Of Azd7624, An Inhaled P38 Map Kinase Inhibitor, In COPD Patients On Ics/laba With A History Of Frequent Exacerbations</title><author>Make, B J ; Patel, N ; Cunoosamy, D ; Brown, M N ; Fageras, M ; Lundin, S ; Asimus, S ; Palmer, R ; Taib, Z ; Jansson, P ; Rennard, S I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_19267191103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Chronic obstructive pulmonary disease</topic><topic>Kinases</topic><topic>Respiratory therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Make, B J</creatorcontrib><creatorcontrib>Patel, N</creatorcontrib><creatorcontrib>Cunoosamy, D</creatorcontrib><creatorcontrib>Brown, M N</creatorcontrib><creatorcontrib>Fageras, M</creatorcontrib><creatorcontrib>Lundin, S</creatorcontrib><creatorcontrib>Asimus, S</creatorcontrib><creatorcontrib>Palmer, R</creatorcontrib><creatorcontrib>Taib, Z</creatorcontrib><creatorcontrib>Jansson, P</creatorcontrib><creatorcontrib>Rennard, S I</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Proquest Health &amp; Medical Complete</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>American journal of respiratory and critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Make, B J</au><au>Patel, N</au><au>Cunoosamy, D</au><au>Brown, M N</au><au>Fageras, M</au><au>Lundin, S</au><au>Asimus, S</au><au>Palmer, R</au><au>Taib, Z</au><au>Jansson, P</au><au>Rennard, S I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>C95 COPD ADVANCES IN THERAPY: A Randomized Controlled Trial Of Azd7624, An Inhaled P38 Map Kinase Inhibitor, In COPD Patients On Ics/laba With A History Of Frequent Exacerbations</atitle><jtitle>American journal of respiratory and critical care medicine</jtitle><date>2017-01-01</date><risdate>2017</risdate><volume>195</volume><issn>1073-449X</issn><eissn>1535-4970</eissn><abstract>Naimish.Patel@astrazeneca.com Prior study has shown that p38 MAP kinase (MAPK) is upregulated in alveolar macrophages in patients with COPD, and p38 activation increases with COPD severity. Events of rash and elevated liver enzymes that have been associated with oral p38 inhibitors were in infrequent (&lt;5%) and not different between the treatment arms.</abstract><cop>New York</cop><pub>American Thoracic Society</pub></addata></record>
fulltext fulltext
identifier ISSN: 1073-449X
ispartof American journal of respiratory and critical care medicine, 2017-01, Vol.195
issn 1073-449X
1535-4970
language eng
recordid cdi_proquest_journals_1926719110
source Freely Accessible Journals; EZB Electronic Journals Library
subjects Chronic obstructive pulmonary disease
Kinases
Respiratory therapy
title C95 COPD ADVANCES IN THERAPY: A Randomized Controlled Trial Of Azd7624, An Inhaled P38 Map Kinase Inhibitor, In COPD Patients On Ics/laba With A History Of Frequent Exacerbations
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T22%3A05%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=C95%20COPD%20ADVANCES%20IN%20THERAPY:%20A%20Randomized%20Controlled%20Trial%20Of%20Azd7624,%20An%20Inhaled%20P38%20Map%20Kinase%20Inhibitor,%20In%20COPD%20Patients%20On%20Ics/laba%20With%20A%20History%20Of%20Frequent%20Exacerbations&rft.jtitle=American%20journal%20of%20respiratory%20and%20critical%20care%20medicine&rft.au=Make,%20B%20J&rft.date=2017-01-01&rft.volume=195&rft.issn=1073-449X&rft.eissn=1535-4970&rft_id=info:doi/&rft_dat=%3Cproquest%3E1926719110%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_19267191103%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1926719110&rft_id=info:pmid/&rfr_iscdi=true